Zimvie

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Westminster, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ZimVie reports Q4 decline, focuses on innovation and challenges

ZimVie's Q4 2022 performance reflected challenges from disruptions in China and spine segment, leading to a decline in net sales.
Despite these challenges, the company showed strength in product innovation, operational efficiencies, and strategic partnerships.
Opportunities lie in focusing on growth through innovation, commercial success, and addressing challenges to improve performance.

ZimVie reports mixed Q1 performance, revises 2023 outlook upwards

ZimVie's Q1 2023 earnings call highlighted a mixed performance with a focus on innovation, financial discipline, and growth potential. While facing challenges in revenue generation and margins, the company's strategic approach and revised outlook indicate opportunities for market expansion and sustained growth.

ZimVie reports strong Q2 earnings, eyes growth in international markets

ZimVie's Q2 2023 earnings call highlighted robust financial performance, strategic initiatives in innovation, and growth prospects in dental and spine segments. The company aims to navigate competitive pressures, capitalize on market trends, and drive profitability through operational efficiencies and product differentiation.

ZimVie reports mixed Q3 results, focuses on innovation and efficiency

ZimVie's Q3 2023 performance reflected mixed results with growth in international dental sales but challenges in the U.S. and spine segments.
Operational efficiency improvements and cash position enhancement are strengths for the company.
Challenges include competition in spine, declining U.S. dental sales, and margin decline, while opportunities lie in market trends and strategic deals.

ZimVie sells spine business for $375 million, targets profitability

ZimVie's Q4 2023 performance reflects a strategic shift towards enhancing profitability through the sale of the spine business and cost optimization initiatives. While facing challenges in market conditions and debt reduction targets, the company aims to capitalize on opportunities for growth and improved financial health.

ZimVie focuses on dental business post-sale, eyes margin growth

ZimVie's Q1 2024 performance reflected a strategic shift towards the dental segment post-spine business sale.
While facing challenges in revenue generation and margin targets, the company's focus on efficiency and innovation bodes well for future growth.
Opportunities lie in margin improvement, market expansion, and new revenue streams through innovative dental solutions.

ZimVie reports robust Q2 revenue, eyes growth amidst short-term challenges

ZimVie's Q2 2024 performance showcased revenue growth and strong commercial traction in key portfolios
Despite short-term revenue challenges, the company reaffirmed full-year guidance and highlighted growth opportunities
Strategic partnerships and product advancements position ZimVie for continued market expansion and innovation
Maintaining financial discipline and focus on profitability amidst market dynamics are key priorities

ZimVie reports solid Q3 earnings, eyes North America for growth

ZimVie's Q3 performance showcased financial stability, strategic investments, and growth in key product portfolios. While challenges like debt management persist, the company's focus on efficiency and innovation positions them well for future opportunities in the dental market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Palm Beach Gardens, FL.

ZimVie Inc. (NASDAQ:ZIMV ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode.

ZimVie Inc. (ZIMV) Q2 2023 Earnings Call Transcript

ZimVie Inc. (ZIMV) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.67 per share a year ago.

ZimVie Inc. (ZIMV) Tops Q2 Earnings and Revenue Estimates

WESTMINSTER, Colo., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the second quarter ended June 30, 2023. Management will host a corresponding conference call today, August 2, 2023, at 4:30 p.m. Eastern Time.

ZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual Guidance

ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?

WESTMINSTER, Colo., July 12, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023

ZimVie's stock price has increased by 19% since November, but the company's fundamentals have deteriorated significantly. The company's revenue guidance for 2023 is set at $848 million, a 6.7% decline from 2022, and LTM CFO has been cut in half from $55 million in Q3/22 to $27 million in Q1/23. With deteriorating fundamentals and higher valuations, I lower the rating on ZIMV to a hold and advise investors to wait for better valuations before considering a position in the company.

ZimVie: Downgrade To A Hold On Valuation And Fundamentals

WESTMINSTER, Colo., May 22, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the company will be participating in the upcoming Stifel 2023 Jaws & Paws Conference in New York. Management will be hosting a presentation on Wednesday, May 31st, 2023, at 12:40 p.m. Eastern Time / 9:40 a.m. Pacific Time. Stifel's Jaws & Paws is a leading conference in the Dental and Animal Health industries.

ZimVie to Present at the Stifel 2023 Jaws & Paws Conference

ZimVie Inc. (NASDAQ:ZIMV ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Richard J. Heppenstall – EVP and CFO Vafa Jamali – President and CEO Marissa Bych - Gilmartin Group Conference Call Participants Robert Marcus - J.P.

ZimVie Inc. (ZIMV) Q1 2023 Earnings Call Transcript

ZimVie Inc. (ZIMV) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.50 per share a year ago.

ZimVie Inc. (ZIMV) Tops Q1 Earnings and Revenue Estimates

New offerings in ZimVie's extensive portfolio of dental bone graft solutions enhance selection for customers and bolster cadence of recent product launches New offerings in ZimVie's extensive portfolio of dental bone graft solutions enhance selection for customers and bolster cadence of recent product launches

ZimVie Announces the Recent Launches of RegenerOss® CC Allograft Particulate and RegenerOss® Bone Graft Plug

WESTMINSTER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report First Quarter 2023 Financial Results on May 3, 2023

Mobi-C obtains French government reimbursement and the highest quality rating from the British clinical data panel ODEP Mobi-C obtains French government reimbursement and the highest quality rating from the British clinical data panel ODEP

ZimVie Announces Expanded Reimbursement and Exemplary Clinical Rating for Mobi-C®

Publication highlights Puros Cancellous Particulate Allograft's collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to competitive freeze-dried allograft solutions Publication highlights Puros Cancellous Particulate Allograft's collagen microstructure and greater surface area for significantly higher mesenchymal stromal cellular (hBMSC) response compared to competitive freeze-dried allograft solutions

ZimVie's Exclusive Puros® Cancellous Particulate Allograft Dental Bone Grafting Solution Excels in Landmark Comparative Study in The International Journal of Oral & Maxillofacial Implants

The Tether™ device now deemed “medically necessary” for the treatment of pediatric scoliosis in additional patients covered by Highmark and BCBS North Dakota The Tether™ device now deemed “medically necessary” for the treatment of pediatric scoliosis in additional patients covered by Highmark and BCBS North Dakota

ZimVie Announces Additional Positive Policy Decisions for Vertebral Body Tethering

The specialty healthcare devices and tech purveyor disappointed with both fourth-quarter figures and full-year guidance.

Why ZimVie Stock Was Plummeting on Thursday

ZimVie Inc. (NASDAQ:ZIMV ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations Vafa Jamali - President & Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Operator Good afternoon and welcome to ZimVie's Fourth Quarter and Full Year 2022 Earnings Conference Call. Currently, all participants are in a listen-only mode.

ZimVie Inc. (ZIMV) Q4 2022 Earnings Call Transcript

WESTMINSTER, Colo., March 01, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the fourth quarter and full year ended December 31, 2022. Management will host a corresponding conference call today, March 1, 2023, at 4:30 p.m. Eastern Time.

ZimVie Reports Fourth Quarter and Full Year 2022 Financial Results

Two innovations enhancing ZimVie's digital dentistry platform Two innovations enhancing ZimVie's digital dentistry platform

ZimVie Announces Launch of the RealGUIDE™ CAD and FULL SUITE Software Modules

WESTMINSTER, Colo., Feb. 13, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full year 2022 after market close on Wednesday, March 1, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Fourth Quarter and Full Year 2022 Financial Results on March 1, 2023

Milestone aligns with ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine Milestone aligns with ten-year anniversary of Mobi-C FDA approval for treatment of one and two levels of the cervical spine

ZimVie Announces Over 200,000 Cervical Discs Have Been Replaced with Mobi-C®

WESTMINSTER, Colo., Dec. 28, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

ZimVie to Present at the 41st Annual J.P. Morgan Healthcare Conference

ZimVie Inc. (NASDAQ:ZIMV ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group IR Vafa Jamali - President and CEO Rich Heppenstall - CFO Conference Call Participants Operator Good afternoon, and welcome to ZimVie's Third Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.

ZimVie Inc. (ZIMV) Q3 2022 Earnings Call Transcript

Newest innovation in ZimVie's digital dentistry platform is designed for immediacy and peri-implant health Newest innovation in ZimVie's digital dentistry platform is designed for immediacy and peri-implant health

ZimVie Announces Launch of Next-Generation TSX™ Implant in the United States

WESTMINSTER, Colo., Oct. 19, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the third quarter 2022 after market close on Wednesday, November 9, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Third Quarter 2022 Financial Results on November 9, 2022

The Virage® Navigation System Rounds out ZimVie's Ability to Navigate Pedicle Screws in the Entire Spine The Virage® Navigation System Rounds out ZimVie's Ability to Navigate Pedicle Screws in the Entire Spine

News for Zimvie Stock (ZIMV)